covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Guía clínica del diagnóstico y tratamiento de la disfunción tiroidea subclí...
Información de la revista
Vol. 54. Núm. 1.
Páginas 44-52 (enero 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 54. Núm. 1.
Páginas 44-52 (enero 2007)
Documentos de los Grupos de Trabajo
Acceso a texto completo
Guía clínica del diagnóstico y tratamiento de la disfunción tiroidea subclínica
Clinical practice guideline for the diagnosis and treatment of subclinical thyroid disease
Visitas
34257
Juan José Corrales Hernández, Núria Alonso Pedrol, Ana Cantón Blanco, Juan Carlos Galofré Ferrater, Antonio Pérez Pérez, Teresa Lajo Morales, Begoña Pérez Corral, Federic Tortosa Henzi
Autor para correspondencia
ftortosah@hotmail.com

Correspondencia: Dr. F. Tortosa Henzi. Departamento de Medicina. Facultad de Medicina. Universidad de Lleida. Avda. Alcalde Rovira Roure, 80. 25198 Lleida. España.
, (Coordinador)
Departamento de Medicina. Facultad de Medicina. Universidad de Lleida. España. Grupo de trabajo de la Sociedad Española de Endocrinología sobre disfunción tiroidea subclínica
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

En la práctica clínica son frecuentes los pacientes con disfunción tiroidea subclínica. Es decir, pacientes con concentraciones de tirotropina (TSH) fuera de los valores de referencia pero con concentraciones de tiroxina libre y triyodotironina libre normales.

En el presente artículo, se describe qué es la disfunción tiroidea subclínica, se revisa su epidemiología, se recomienda el abordaje más apropiado, se evalúan los riesgos y beneficios del tratamiento y se establece la utilidad de su cribado en ciertos grupos de población.

En definitiva, son limitadas las evidencias que sugieren una asociación de la disfunción tiroidea subclínica con ciertos síntomas o con el beneficio o riesgos de su tratamiento. Las consecuencias de la disfunción tiroidea subclínica (TSH: 0,1-0,45 mU/l o 4,5-10 mU/l) son escasas y no se puede recomendar el tratamiento rutinario de estos pacientes. Asimismo, no se puede recomendar el cribado indiscriminado de la población. No obstante, se debe buscar con insistencia en mujeres embarazadas de riesgo, mujeres mayores de 60 años y en ciertos grupos de riesgo.

Palabras clave:
Disfunción tiroidea subclínica
Hipertiroidismo subclínico
Hipotiroidismo subclínico

Patients with serum thyroidstimulating hormone (TSH) outside the reference range and levels of free thyroxine and free triiodothyronine within the reference range are common in clinical practice. In the present article, subclinical thyroid disease is defined and its epidemiology reviewed.

Recommendations on appropriate evaluation and the risks and benefits of treatment and consequences of non-treatment are explored. The question of whether population-based screening is warranted is also discussed.

Data supporting an association between subclinical thyroid disease and symptoms or adverse clinical outcomes or benefits of treatment are scarce. The consequences of subclinical thyroid disease (serum TSH 0.1-0.45 mU/l or 4.5-10.0 mU/l) are minimal and recommendations against routine treatment of patients with TSH levels in these ranges are provided. There is insufficient evidence to support population-based screening. Nevertheless, pertinacious case finding is appropriate in pregnant women at risk, women older than 60 years, and others at high risk for thyroid dysfunction.

Key words:
Subclinical thyroid disease
Subclinical hyperthyroidism
Subclinical hypothyroidism
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.I. Surks, E. Ortiz, G.H. Daniels, C.T. Sawin, N.F. Col, R.H. Cobin, et al.
Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management.
JAMA, 291 (2004), pp. 228-238
[2.]
A.R. Cappola, L.P. Fried, A.M. Arnold, M.D. Danese, L.H. Kuller, G.L. Burke, et al.
Thyroid status, cardiovascular risk, and mortality in older adults.
JAMA, 295 (2006), pp. 1033-1041
[3.]
G.R. Wilson, R.W. Curry Jr.
Subclinical thyroid disease.
Am Fam Physician, 72 (2005), pp. 1517-1524
[4.]
G. Papi, E.N. Pearce, L.E. Braverman, C. Betterle, E. Roti.
A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only.
Am J Med, 118 (2005), pp. 349-361
[5.]
H. Gharib, R.M. Tuttle, H.J. Baskin, L.H. Fish, P.A. Singer, M.T. McDermott.
Consensus Statement. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, The American Thyroid Association and The Endocrine Society.
J Clin Endocrinol Metab, 90 (2004), pp. 581-585
[6.]
G.J. Canaris, N.R. Manowitz, G. Mayor, E.C. Ridgway.
The Colorado thyroid disease prevalence study.
Arch Int Med, 160 (2000), pp. 526-534
[7.]
J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, et al.
Serum TSH, T4 and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).
J Clin Endocrinol Metab, 87 (2002), pp. 489-499
[8.]
E. Gasco Eguiluz, M.C. Serna Arnaiz, A. Vázquez Torguet, M. Peremiquel Lluch, M. Ibarra Excuer, L. Serra Majem.
La prevalencia de trastornos funcionales tiroideos en la provincia de Lleida.
Aten Primaria, 24 (1999), pp. 475-479
[9.]
J.J. Díez, I. Molina, M.T. Ibars.
Prevalence of thyroid dysfunction in adults over age 60 years from an urban community.
Exp Clin Endocrinol Diabetes, 111 (2003), pp. 480-485
[10.]
J.C. Galofré, R.V.G. García-Mayor, E. Fluiters, L. Fernández-Calvet, A. Rego, C. Páramo, et al.
Incidence of different forms of thyroid dysfunction and its degrees in an iodine sufficient area.
Thyroidol Clin Exp, 6 (1994), pp. 49-54
[11.]
C.T. Sawin.
Subclinical hyperthyroidism and atrial fibrillation.
Thyroid, 12 (2002), pp. 501-503
[12.]
C.T. Sawin, A. Geller, P.A. Wolf, A.J. Belanger, E. Baker, P. Bacharach, et al.
Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.
N Engl J Med, 331 (1994), pp. 1249-1252
[13.]
B. Uzzan, J. Campos, M. Cucherat, P. Nony, J.P. Boissel, G.Y. Perret.
Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis.
J Clin Endocrinol Metab, 81 (1996), pp. 4278-4289
[14.]
D.C. Bauer, B. Ettinger, M.C. Nevitt, K.L. Stone.
Study of Osteoporotic Fractures Research Group. Risk for fracture in women with low serum levels of thyroid-stimulating hormone.
Ann Intern Med, 134 (2001), pp. 561-568
[15.]
J.V. Parle, P. Maisonneuve, M.C. Sheppard, P. Boyle, J.A. Franklyn.
Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study.
[16.]
B. Biondi, E.A. Palmieri, M. Klain, M. Schlumberger, S. Filetti, G. Lombardi.
Subclinical hyperthyroidism: clinical features and treatment options.
Eur J Endocrinol, 152 (2005), pp. 1-9
[17.]
N.F. Col, M.I. Surks, G.H. Daniels.
Subclinical thyroid disease: clinical applications.
JAMA, 291 (2004), pp. 239-243
[18.]
E.N. Pearce, A.P. Farwell, L.E. Braverman.
Thyroiditis.
N Engl J Med, 348 (2003), pp. 2646-2655
[19.]
D.S. Cooper.
Subclinical hypothyroidism.
N Engl J Med, 345 (2001), pp. 260-265
[20.]
C.T. Sawin, W.P. Castelli, J.M. Hershman, P. McNamara, P. Bacharat.
The agin thyroid: thyroid deficiency in the Framingham study.
Arch Int Med, 145 (1985), pp. 1386-1388
[21.]
C. Meier, J.J. Staub, C.B. Roth, M. Guglielmetti, M. Kunz, A.R. Miserez, et al.
TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study).
J Clin Endocrinol Metab, 86 (2001), pp. 4860-4866
[22.]
M.P. Vanderpump, W.M. Tunbridge, J.M. French, D. Appleton, D. Bates, F. Clark, et al.
The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey.
Clin Endocrinol, 43 (1995), pp. 55-68
[23.]
A.E. Hak, H.A. Pols, T.J. Visser, H.A. Drexhage, A. Hofman, J.C. Witteman.
Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study.
Ann Intern Med, 132 (2000), pp. 270-278
[24.]
R.D. Lindeman, L.J. Romero, D.S. Schade, S. Wayne, R.N. Baumgartner, P.J. Garry.
Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey.
Thyroid, 13 (2003), pp. 595-600
[25.]
J.P. Walsh, A.P. Bremner, M.K. Bulsara, P. O’leary, P.J. Leedman, P. Feddema, et al.
Subclinical thyroid dysfunction as a risk factor for cardiovascular disease.
Arch Intern Med, 165 (2005), pp. 2467-2472
[26.]
N. Rodondi, A.B. Newman, E. Vittinghoff, N. De Rekeneire, S. Satterfield, T.B. Harris, et al.
Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death.
Arch Intern Med, 165 (2005), pp. 2460-2466
[27.]
F. Monzani, V. Di Bello, N. Caraccio, A. Bertini, D. Giorgi, C. Giusti, et al.
Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study.
J Clin Endocrinol Metab, 86 (2001), pp. 1110-1115
[28.]
M.D. Danese, P.W. Ladenson, C.L. Meinert, N.R. Powe.
Effect of thyroixine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literatura.
J Clin Endocrino Metab, 85 (2000), pp. 2993-3001
[29.]
A. Pérez, J.M. Cubero, N. Sucunza, E. Ortega, R. Arcelus, J. Rodríguez-Espinosa, et al.
Emerging cardiovascular risk factors in subclinical hypothyroidism: lack of change after restoration of euthyroidism.
Metabolism, 53 (2004), pp. 1512-1515
[30.]
M. Christ-Crain, C. Meier, M. Guglielmetti, P.R. Huber, W. Riesen, J.J. Staub, et al.
Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial.
Atherosclerosis, 166 (2003), pp. 379-386
[31.]
M. Imaizumi, M. Akahoshi, S. Ichimaru, E. Nakashima, A. Hida, M. Soda, T. Usa, et al.
Risk for ischemic heart disease and allcause mortality in subclinical hypothyroidism.
J Clin Endocrinol Metab, 89 (2004), pp. 3365-3370
[32.]
J. Gussekloo, E. Van Exel, A.J. De Craen, A.E. Meinders, M. Frölich, R.G. Westendrop.
Thyroid status, disability and cognitive function, and survival in old age.
JAMA, 292 (2004), pp. 2591-2599
[33.]
J.J. Díez.
Hipotiroidismo subclínico.
Endocrinol Nutr, 52 (2005), pp. 251-259
[34.]
Thyroid disease in pregnancy.
ACOG Practice Buletin. N.° 37. American College of Obstetricians and Gynecologists.
Obstet Gynecol, 100 (2002), pp. 387
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos